NTVH - 2023, nummer Special, september 2023
dr. Matteo Giovanni Della Porta
Transfusie-afhankelijke patiënten met een laag risico myelodysplastisch syndroom hebben te maken met: chronische anemie, verhoogde morbiditeit, ijzeroverbelasting en een slechte algehele overleving. Tijdens EHA 2023 presenteerde dr. Matteo Giovanni Della Porta (Cancer Center Irccs Humanitas Research Hospital, Milaan, Italië) de interim-analyse van de fase III-studie COMMANDS, waarin luspatercept wordt vergeleken met epoëtine alfa bij patiënten met een laag risico myelodysplastisch syndroom, die niet eerder waren behandeld met erytropoëtine-stimulerende middelen.1,2
Lees verderTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
